Argentina Glp-1 Receptor Agonist Market Size & Outlook
Global Market
Related Markets
Argentina glp-1 receptor agonist market highlights
- The Argentina glp-1 receptor agonist market generated a revenue of USD 302.5 million in 2025 and is expected to reach USD 1,070.4 million by 2033.
- The Argentina market is expected to grow at a CAGR of 15.9% from 2026 to 2033.
- In terms of segment, semaglutide (ozempic, wegovy, rybelsus) was the largest revenue generating product in 2025.
- Tirzepatide (Mounjaro, Zepbound) is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2025 | USD 302.5 million |
| Market revenue in 2033 | USD 1,070.4 million |
| Growth rate | 15.9% (CAGR from 2026 to 2033) |
| Largest segment | Semaglutide (ozempic, wegovy, rybelsus) |
| Fastest growing segment | Tirzepatide (Mounjaro, Zepbound) |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro, Zepbound), Dulaglutide (Trulicity), Liraglutide (Victoza, Saxenda), Others (Byetta, Bydureon, SOLIQUA) |
| Key market players worldwide | Eli Lilly and Co, Sanofi SA, Novo Nordisk A/S ADR, AstraZeneca PLC |
Other key industry trends
- In terms of revenue, Argentina accounted for 0.5% of the global glp-1 receptor agonist market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Latin America, Brazil glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2033.
- Argentina is the fastest growing regional market in Latin America and is projected to reach USD 1,070.4 million by 2033.
Government support to improve the healthcare system and facilitate access to advanced diagnosis & treatment is expected to fuel the market in Argentina. The pharmaceutical sector in the country is robust, featuring 402 licensed manufacturers—362 specializing in pharmaceutical products and 40 in starting materials.
Researchers in the country possess the capability for comprehensive pharmaceutical activities, including R&D to discover new active substances, produce Active Pharmaceutical Ingredients (APIs), formulate pharmaceutical products from them, and repackage finished dosage forms.
This infrastructure supports a well-rounded pharmaceutical industry with significant potential for both innovation and production. The market growth is attributed to the rising prevalence of diabetes in the country and the steps taken to promote initiatives that contribute to reducing the rise of overweight & obesity among the population.
No credit card required*
Publish Date: Dec 23, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Glenmark Pharmaceuticals | View profile | 10001+ | Andheri, Maharashtra, India, Asia | www.glenmarkpharma.com |
Argentina GLP-1 Receptor Agonist Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to GLP-1 Receptor Agonist Market Outlook will help companies and investors design strategic landscapes.
Semaglutide (Ozempic, Wegovy, Rybelsus) was the largest segment with a revenue share of 86.12% in 2025.
Horizon Databook has segmented the Argentina glp-1 receptor agonist market based on semaglutide (ozempic, wegovy, rybelsus), tirzepatide (mounjaro, zepbound), dulaglutide (trulicity), liraglutide (victoza, saxenda), others (byetta, bydureon, soliqua) covering the revenue growth of each sub-segment from 2021 to 2033.
Government support to improve the healthcare system and facilitate access to advanced diagnosis & treatment is expected to fuel the market in Argentina. The pharmaceutical sector in the country is robust, featuring 402 licensed manufacturers—362 specializing in pharmaceutical products and 40 in starting materials.
Researchers in the country possess the capability for comprehensive pharmaceutical activities, including R&D to discover new active substances, produce Active Pharmaceutical Ingredients (APIs), formulate pharmaceutical products from them, and repackage finished dosage forms.
This infrastructure supports a well-rounded pharmaceutical industry with significant potential for both innovation and production. The market growth is attributed to the rising prevalence of diabetes in the country and the steps taken to promote initiatives that contribute to reducing the rise of overweight & obesity among the population.
- Argentina Glp-1 Receptor Agonist Market Product Outlook (Revenue, USD Million , 2021-2033)
- Semaglutide (Ozempic, Wegovy, Rybelsus)
- Tirzepatide (Mounjaro, Zepbound)
- Dulaglutide (Trulicity)
- Liraglutide (Victoza, Saxenda)
- Others (Byetta, Bydureon, SOLIQUA)
- Argentina Glp-1 Receptor Agonist Market Application Outlook (Revenue, USD Million , 2021-2033)
- Type 2 Diabetes Mellitus
- Obesity / Chronic Weight Management
- Cardiovascular Risk
- Argentina Glp-1 Receptor Agonist Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Injectable / Parenteral
- Oral
- Argentina Glp-1 Receptor Agonist Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Reasons to subscribe to GLP-1 Receptor Agonist Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of GLP-1 Receptor Agonist Market Outlook databook
- Our clientele includes a mix of GLP-1 Receptor Agonist Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina GLP-1 Receptor Agonist Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Argentina GLP-1 Receptor Agonist Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Argentina Glp-1 Receptor Agonist Market, 2021-2033 (US$M)
Argentina glp-1 receptor agonist market statistics, by product, 2021-2033 (US$M)
